Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Vis graf over relationer


Immunology, Biotechnology, Tumor immunology

Primære forskningsområder

The immune system often fails to respond effectively against immunogenic antigens and become tolerant towards these antigens. We need to overcome this acquired state of tolerance for cancer immunotherapy to succeed. Immune regulatory proteins; e.g., programmed death-ligand 1 (PD-L1), PD-L2,  indoleamine 2,3-dioxygenase (IDO), IDO2, tryptophan 2,3-dioxygenase (TDO), forkhead box P3 (Foxp3), and FoxO3 play a vital role in the immune suppression and tolerance induction of anti cancer immune responses. The main research area covers characterization and identification of self-reactive T cells that specifically recognized human leukocyte antigen (HLA)-restricted epitopes derived from these immune regulatory proteins.

Aktuel forskning

My current research is based on identification and characterization of  immune response against Programmed Cell Death Ligand 1 and 2 (PD-L1 and PD-L2) epitopes.

ID: 36544223